Subscribe To
COGT / Cogent Biosciences: Bezuclastinib's Potential In Treating Gastrointestinal Stromal Tumors
COGT News
By GuruFocus
July 7, 2023
3 Lost Formula Stocks to Consider for the 2nd Half of 2023
Having ended 2022 on a low note, U.S. market indexes have overall shown stronger performances so far in 2023. more_horizontal
By Seeking Alpha
February 28, 2023
Cogent Biosciences: Bezuclastinib's Potential In Treating Gastrointestinal Stromal Tumors
Cogent Biosciences is a biotechnology company focused on developing solutions for complex medical conditions, with a particular focus on Gastrointesti more_horizontal
By Seeking Alpha
December 27, 2022
Cogent Biosciences: Multiple Inflection Points For FY23, Hold For Now
Cogent Biosciences, Inc. is building momentum around its bezuclastinib compound. FY22 saw a number of positive advancements of the company's pipeline. more_horizontal
By GlobeNewsWire
December 5, 2022
Cogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis
WALTHAM, Mass. and BOULDER, Colo., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on dev more_horizontal
By InvestorPlace
June 10, 2022
Cogent Biosciences (COGT) Stock Soars 90% on Positive Clinical Data
Today, investors in Cogent Biosciences and COGT stock have some promising clinical trial results to look at, as this stock soars. The post Cogent Bio more_horizontal